Geode Capital Management LLC Sells 4,531 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Geode Capital Management LLC trimmed its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.2% in the 2nd quarter, Holdings Channel.com reports. The fund owned 2,465,054 shares of the biopharmaceutical company’s stock after selling 4,531 shares during the quarter. Geode Capital Management LLC’s holdings in Regeneron Pharmaceuticals were worth $1,288,520,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in REGN. Vanguard Group Inc. grew its stake in Regeneron Pharmaceuticals by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 9,407,891 shares of the biopharmaceutical company’s stock worth $5,966,767,000 after buying an additional 121,545 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in Regeneron Pharmaceuticals by 4.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,175,026 shares of the biopharmaceutical company’s stock valued at $1,379,467,000 after purchasing an additional 89,579 shares in the last quarter. Amundi increased its stake in Regeneron Pharmaceuticals by 3.4% during the 1st quarter. Amundi now owns 1,603,901 shares of the biopharmaceutical company’s stock valued at $979,794,000 after purchasing an additional 52,166 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 18.0% in the first quarter. Goldman Sachs Group Inc. now owns 1,143,093 shares of the biopharmaceutical company’s stock worth $724,984,000 after buying an additional 174,056 shares during the last quarter. Finally, American Century Companies Inc. increased its position in shares of Regeneron Pharmaceuticals by 2.1% in the 1st quarter. American Century Companies Inc. now owns 722,467 shares of the biopharmaceutical company’s stock valued at $458,211,000 after acquiring an additional 14,921 shares during the period. 83.31% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. Bank of America increased their price objective on shares of Regeneron Pharmaceuticals from $543.00 to $627.00 and gave the stock an “underperform” rating in a research note on Wednesday, October 29th. Jefferies Financial Group increased their price target on Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the stock a “buy” rating in a research report on Wednesday, August 27th. Guggenheim boosted their price objective on Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. Truist Financial dropped their target price on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a “buy” rating on the stock in a report on Monday, August 11th. Finally, Morgan Stanley reduced their price target on Regeneron Pharmaceuticals from $761.00 to $756.00 and set an “overweight” rating for the company in a research report on Friday, October 10th. Three analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $796.57.

Regeneron Pharmaceuticals Stock Up 1.1%

Shares of REGN opened at $681.72 on Thursday. The firm has a market cap of $71.65 billion, a P/E ratio of 16.32, a PEG ratio of 2.03 and a beta of 0.31. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $823.56. The stock’s 50 day moving average is $593.81 and its two-hundred day moving average is $569.58. The company has a current ratio of 4.06, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $9.73 by $2.10. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The firm had revenue of $3.75 billion for the quarter, compared to analyst estimates of $3.57 billion. During the same quarter last year, the firm posted $12.46 EPS. The business’s revenue was up .9% on a year-over-year basis. Analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, December 5th. Stockholders of record on Thursday, November 20th will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Thursday, November 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is currently 8.43%.

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 431 shares of the stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $651.43, for a total transaction of $280,766.33. Following the completion of the transaction, the vice president owned 4,233 shares of the company’s stock, valued at $2,757,503.19. This represents a 9.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Christine A. Poon sold 6,500 shares of the business’s stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total value of $4,252,755.00. Following the sale, the director owned 2,352 shares of the company’s stock, valued at $1,538,843.04. The trade was a 73.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 7.02% of the stock is owned by insiders.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.